[5-(三氟甲基)-2-呋喃基]甲胺 | 868755-68-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: [5-(三氟甲基)-2-呋喃基]甲胺
• 中文别名: C-(5-三氟甲基-呋喃-2-基)甲胺
• 英文名称: 2-aminomethyl-5-trifluoromethylfurane
• 英文别名: 2-(aminomethyl)-5-(trifluoromethyl)furan；1-[5-(Trifluoromethyl)furan-2-Yl]methanamine；[5-(trifluoromethyl)furan-2-yl]methanamine
• CAS: 868755-68-4
• 化学式: C₆H₆F₃NO
• mdl: MFCD03086222
• 分子量: 165.115
• InChiKey: MMOMFJIMQXUJMQ-UHFFFAOYSA-N

物化性质

• 沸点：
  90 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  39.2
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险品标志：
  C

反应信息

• 作为反应物：
  描述：

  [5-(三氟甲基)-2-呋喃基]甲胺 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-(3-oxo-4H-1,4-benzoxazin-8-yl)-3-[[5-(trifluoromethyl)-2-furyl]methyl]urea
  参考文献：
  名称：

  [EN] "TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION"
  [FR] ANTAGONISTES DU RÉCEPTEUR VANILLOÏDE TRPV1 AYANT UNE PARTIE BICYCLIQUE

  摘要：

  该发明揭示了公式I的化合物，其中Y是公式A、B、C、D或E的一个基团；W、Q、n、R1、R2、R3、U1-U5、J和K具有描述中给出的含义。公式I的化合物是TRPV1拮抗剂，可用作药物组合物的活性成分，用于治疗通过抑制辣椒素受体TRPV1而改善的疼痛和其他病症。

  公开号：

  WO2011120604A1

文献信息

• The Influence of Substitution on Thiol-Induced Oxanorbornadiene Fragmentation
  作者：Lucrezia De Pascalis、Mei-Kwan Yau、Dennis Svatunek、Zhuoting Tan、Srinivas Tekkam、K. N. Houk、M. G. Finn

  DOI：10.1021/acs.orglett.1c01164

  日期：2021.5.7

  Oxanorbornadienes (ONDs) undergo facile Michael addition with thiols and then fragment by a retro-Diels–Alder (rDA) reaction, a unique two-step sequence among electrophilic cleavable linkages. The rDA reaction rate was explored as a function of the furan structure, with substituents at the 2- and 5-positions found to be the most influential and the fragmentation rate to be inversely correlated with

  氧杂降冰片二烯 (OND) 与硫醇进行简单的迈克尔加成，然后通过逆狄尔斯-阿尔德 (rDA) 反应进行片段化，这是亲电可切割键之间的独特两步序列。研究了 rDA 反应速率与呋喃结构的函数关系，发现 2 位和 5 位的取代基影响最大，碎裂率与吸电子能力呈负相关。密度泛函理论计算提供了与实验测量的 OND rDA 率的极好相关性。
• TRPV1 vanilloid receptor antagonists with a bicyclic portion
  申请人：Pharmeste S.r.l.

  公开号：EP2377850A1

  公开（公告）日：2011-10-19

  The invention discloses compounds of formula I wherein Y s selected from a group of formula and W, Q, n, R1, R2, R3, U1-U5 have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1. 1.

  该发明揭示了以下式的化合物： 其中Y选自以下式的一组 而W、Q、n、R1、R2、R3、U1-U5的含义如描述中所给出。 该式化合物是TRPV1拮抗剂，可用作药物组合物的活性成分，用于治疗疼痛和其他通过抑制辣椒素受体TRPV1而改善的症状。
• TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION
  申请人：Napoletano Mauro

  公开号：US20130079339A1

  公开（公告）日：2013-03-28

  The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1.

  该发明揭示了化合物I的公式，其中Y是公式A、B、C、D或E的一个基团：W、Q、n、R1、R2、R3、U1-U5、J和K的含义如描述中所述。公式I的化合物是TRPV1拮抗剂，并且作为制药组合物的活性成分用于治疗疼痛和其他通过抑制vanilloid受体TRPV1改善的病症。
• Pyridazinone derivatives useful as glucan synthase inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2586778A2

  公开（公告）日：2013-05-01

  In its many embodiments, the present invention provides -substituted pyridazinone compounds as glucan synthase inhibitors, methods of preparing such compounds, pharmaceutical including one or more of such compounds, methods of preparing pharmaceutical formulations including one or more such compounds or one or more such compounds along with other antifungal agents, and methods of treatment, prevention, inhibition, or amelioration of one or more fungal infections associated with glucan synthase using such compounds or pharmaceutical compositions.

  在其许多实施方案中，本发明提供了作为葡聚糖合成酶抑制剂的-取代哒嗪酮化合物、制备此类化合物的方法、包括一种或多种此类化合物的药物、制备包括一种或多种此类化合物或一种或多种此类化合物与其他抗真菌剂的药物制剂的方法，以及使用此类化合物或药物组合物治疗、预防、抑制或改善与葡聚糖合成酶相关的一种或多种真菌感染的方法。
• Discovery of Piperazin-1-ylpyridazine-Based Potent and Selective Stearoyl-CoA Desaturase-1 Inhibitors for the Treatment of Obesity and Metabolic Syndrome
  作者：Zaihui Zhang、Shaoyi Sun、Vishnumurthy Kodumuru、Duanjie Hou、Shifeng Liu、Nagasree Chakka、Serguei Sviridov、Sultan Chowdhury、David G. McLaren、Leslie G. Ratkay、Kuldip Khakh、Xing Cheng、Heinz W. Gschwend、Rajender Kamboj、Jianmin Fu、Michael D. Winther

  DOI：10.1021/jm301661h

  日期：2013.1.24

  Stearoyl-CoA desaturase-1 (SCD1) catalyzes de novo synthesis of monounsaturated fatty acids from saturated fatty acids. Studies have demonstrated that rodents lacking a functional SCD1 gene have an improved metabolic profile, including reduced weight gain, lower triglycerides, and improved insulin response. In this study, we discovered a series of piperazinylpyridazine-based highly potent, selective, and orally bioavailable compounds. Particularly, compound 49 (XEN103) was highly active in vitro (mSCD1 IC50 = 14 nM and HepG2 IC50 = 12 nM) and efficacious in vivo (ED50 = 0.8 mg/kg). It also demonstrated striking reduction of weight gain in a rodent model. Our findings with small-molecule SCD1 inhibitors confirm the importance of this target in metabolic regulation, describe novel models for assessing SCD1 inhibitors for efficacy and tolerability and demonstrate an opportunity to develop a novel therapy for metabolic disease.

表征谱图